Live feed19:30:00·871dPRReleasevia QuantisnowLatest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported OutcomesByQuantisnow·Wall Street's wire, on your screen.REGN· Regeneron Pharmaceuticals Inc.Health Care